Yutaka Furuta

Dr. Yutaka Furuta

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2024 in Genes
Verified
Journal Article
Open access
PDF file
HGHanabi Geiger
Hanabi Geiger
YFYutaka Furuta
Yutaka Furuta
SWSune van Wyk
Sune van Wyk
JIJohn Atlas Phillips III
John Atlas Phillips III
RTRory J Tinker
Rory J Tinker
Genetic mosaicism is defined as the presence of two or more cell lineages with different genotypes arising from a single zygote. Mosaicism has been implicated in hundreds of genetic diseases with diverse genetic etiologies affecting every organ system. Mosaic genetic disease (MDG) is a spectrum that, on the extreme ends, enables survival from genetic severe disorders that would be lethal in a non-mosaic form. On the milder end of the spectrum, mosaicism can result in little if any phenotypic effects but increases the risk of transmitting a pathogenic genotype. In the middle of the spectrum, mosaicism has been implicated in reducing the phenotypic severity of genetic disease. In this review will describe the spectrum of mosaic genetic disease whilst discussing the status of the detection and prevalence of mosaic genetic disease.

14 November 2024 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
YFYutaka Furuta
Yutaka Furuta
RTRory J. Tinker
Rory J. Tinker
RHRizwan Hamid
Rizwan Hamid
JCJoy D. Cogan
Joy D. Cogan
KEKimberly M. Ezell
Kimberly M. Ezell
TNThe Undiagnosed Diseases Network
The Undiagnosed Diseases Network
Background: The number of known inherited metabolic diseases (IMDs) has been expanding, and the rate of diagnosis is improving with the development of innovative approaches including next generation sequencing (NGS). However, a substantial proportion of IMDs remain undetected by traditional diagnostic approaches. We aim to highlight the spectrum of IMDs diagnosed by the Undiagnosed Diseases Network (UDN) and to learn from the UDN diagnostic processes that were able to detect IMDs. Methods: We conducted a retrospective analysis of 757 UDN participants diagnosed from 2015 until 2023 using the cohort database, which were divided into a cohort with IMDs (n = 194; 27%) and a cohort whose phenotypes were not explained by an IMD (n = 563; 73%), based on the International Classification of Inherited Metabolic Disorders (ICIMD). Then, we divided the causes of the metabolic 194 diagnoses into seven groups that included all the ICIMD categories. We inspected which clinical and laboratory approaches contributed to a final UDN diagnosis. We also present a UDN case example from each group to highlight the diagnostic yields that resulted from combining newer diagnostic approaches in the UDN and illustrate potential pitfalls of current NGS methods. Results: These 194 cases of IMDs included examples from 21/25 (84%) of the ICIMD categories. Of the UDN subjects 164/194 (85%) were diagnosed with IMDs through NGS. Conclusion: The spectrum of IMDs detected in the UDN cohort is large and growing and appropriate use of newer multiple diagnostic approaches should further increase diagnosis of IMDs that are presently missed by the traditional laboratory screening methods.

16 January 2024 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
RTRory J Tinker
Rory J Tinker
LBLisa Bastarache
Lisa Bastarache
KEKimberly Ezell
Kimberly Ezell
SNSerena M. Neumann
Serena M. Neumann
YFYutaka Furuta
Yutaka Furuta
JPJohn A. Phillips
John A. Phillips

27 September 2024 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
AGAlex F. Gimeno
Alex F. Gimeno
RTRory J Tinker
Rory J Tinker
YFYutaka Furuta
Yutaka Furuta
UNUndiagnosed Diseases Network
Undiagnosed Diseases Network
JPJohn A. Phillips
John A. Phillips
Report the prevalence of multiple genetic diseases in the Undiagnosed Diseases Network (UDN) cohort in the post‐exome‐sequencing era. UDN subjects underwent genome sequencing before inclusion in the cohort. Records of all UDN subjects until January 2024 were analyzed. The number of diagnoses, proportion of molecular versus nonmolecular (i.e., not attributable to a discretely identifiable genetic change) diagnoses, and the inheritance patterns of the genetic diagnoses were determined. Of 2799 subjects, 766 (27.4%) had diagnoses. Of these 766, 95.4% had one diagnosis, 4.0% had two diagnoses, and 0.5% had three diagnoses. Of the diagnosed subjects, 93.4% had a genetic disease, and 6.5% had a nonmolecular disease. Of subjects with two diagnoses, both diagnoses were molecular in 90.3%, while 9.7% had one molecular and one nonmolecular diagnosis. All four subjects with three diagnoses had three molecular diagnoses. 4.2% of diagnosed subjects in the UDN had more than one molecular diagnosis, with four individuals having three concurrent Mendelian diagnoses. Additionally, three subjects had concurrent molecular and nonmolecular diagnoses. Given that numerous UDN subjects had a negative genome sequence prior to UDN enrollment, multiple molecular diagnoses may contribute to diagnostic uncertainty even with genome sequencing, as may concurrent nonmolecular disease.

21 March 2024 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
KEKimberly M. Ezell
Kimberly M. Ezell
RTRory J. Tinker
Rory J. Tinker
YFYutaka Furuta
Yutaka Furuta
AGAlican Gulsevin
Alican Gulsevin
LBLisa Bastarache
Lisa Bastarache
TNThe Undiagnosed Diseases Network
The Undiagnosed Diseases Network
The Undiagnosed Disease Network (UDN) is comprised of clinical and research experts collaborating to diagnose rare disease. The UDN is funded by the National Institutes of Health and includes 12 different clinical sites (About Us, 2022). Here we highlight the success of collaborative efforts within the UDN Clinical Site at Vanderbilt University Medical Center (VUMC) in utilizing a cohort of experts in bioinformatics, structural biology, and genetics specialists in diagnosing rare disease. Our UDN team identified a de novo mosaic CACNA1D variant c.2299T>C in a 5‐year‐old female with a history of global developmental delay, dystonia, dyskinesis, and seizures. Using a collaborative multidisciplinary approach, our VUMC UDN team diagnosed the participant with Primary Aldosteronism, Seizures, and Neurologic abnormalities (PASNA) OMIM: 615474 due to a rare mosaic CACNA1D variant (O'Neill, 2013). Interestingly, this patient was mosaic, a phenotypic trait previously unreported in PASNA cases. This report highlights the importance of a multidisciplinary approach in diagnosing rare disease.

27 October 2023 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
YFYutaka Furuta
Yutaka Furuta
RTRory J Tinker
Rory J Tinker
AGAlican Gulsevin
Alican Gulsevin
SNSerena M. Neumann
Serena M. Neumann
RHRizwan Hamid
Rizwan Hamid
TNThe Undiagnosed Diseases Network
The Undiagnosed Diseases Network